<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7298724</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">32540630</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">7298724</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">S2213-1582(20)30124-8</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1016/j.nicl.2020.102287</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">102287</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Patient characteristics.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0005"><label>Table 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td/><td>n</td><td>%</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td><bold>Gender</bold></td><td/><td/></tr><tr><td> male/female</td><td>50/30</td><td>63/37</td></tr><tr><td><bold>Age</bold> (years)</td><td/><td/></tr><tr><td> 25–30</td><td>3</td><td>4</td></tr><tr><td> 30–40</td><td>10</td><td>13</td></tr><tr><td> 40–50</td><td>20</td><td>25</td></tr><tr><td> 50–60</td><td>26</td><td>33</td></tr><tr><td> 60–70</td><td>15</td><td>19</td></tr><tr><td> 70–80</td><td>5</td><td>6</td></tr><tr><td> 81</td><td>1</td><td>1</td></tr><tr><td><bold>Performance Status</bold> (ECOG Scale)</td><td/><td/></tr><tr><td> ECOG 0</td><td>36</td><td>45</td></tr><tr><td> ECOG 1</td><td>37</td><td>46</td></tr><tr><td> ECOG 2</td><td>6</td><td>8</td></tr><tr><td> ECOG 3</td><td>1</td><td>1</td></tr><tr><td><bold>Tumor Type</bold></td><td/><td/></tr><tr><td> Glioblastoma, IDH wildtype</td><td>46</td><td>58</td></tr><tr><td> Glioblastoma, IDH mutant</td><td>8</td><td>10</td></tr><tr><td> Glioblastoma, NOS</td><td>3</td><td>4</td></tr><tr><td> Anaplastic astrocytoma, IDH wildtype</td><td>4</td><td>5</td></tr><tr><td> Anaplastic astrocytoma, IDH mutant</td><td>7</td><td>9</td></tr><tr><td> Anaplastic astrocytoma, NOS</td><td>4</td><td>5</td></tr><tr><td> Anaplastic Oligodendroglioma, IDH mutant, 1p/19q co-deleted</td><td>8</td><td>10</td></tr><tr><td><bold>Tumor Location</bold></td><td/><td/></tr><tr><td> frontal left/frontal right</td><td>19/19</td><td>24/24</td></tr><tr><td> parietal left/parietal right</td><td>5/5</td><td>6/6</td></tr><tr><td> temporal left/temporal right</td><td>14/12</td><td>18/15</td></tr><tr><td> occipital left/occipital right</td><td>5/1</td><td>6/1</td></tr><tr><td><bold>Primary Treatment<sup>#</sup></bold></td><td/><td/></tr><tr><td> Resection + RT + TMZ/CCNU/PC</td><td>58</td><td>70</td></tr><tr><td> Biopsy + RT + TMZ/CCNU/PC</td><td>10</td><td>13</td></tr><tr><td> Resection + RT</td><td>5</td><td>6</td></tr><tr><td> Resection alone</td><td>6</td><td>8</td></tr><tr><td> Biopsy + RT</td><td>1</td><td>1</td></tr><tr><td><bold>Total Number of Oncologic Interventions*</bold></td><td/><td/></tr><tr><td> 1</td><td>6</td><td>8</td></tr><tr><td> 2</td><td>3</td><td>4</td></tr><tr><td> 3</td><td>61</td><td>76</td></tr><tr><td> 4</td><td>2</td><td>3</td></tr><tr><td> 5</td><td>6</td><td>8</td></tr><tr><td> 7</td><td>2</td><td>3</td></tr><tr><td><bold>Recurrence diagnosed by FET PET</bold></td><td/><td/></tr><tr><td> no/yes</td><td>43/37</td><td>54/46</td></tr><tr><td><bold>Neurological Symptoms</bold></td><td/><td/></tr><tr><td> None</td><td>25</td><td>31</td></tr><tr><td> Paresis</td><td>19</td><td>23</td></tr><tr><td> Aphasia</td><td>15</td><td>19</td></tr><tr><td> Fatigue</td><td>10</td><td>13</td></tr><tr><td> Visual Field Defect</td><td>7</td><td>9</td></tr><tr><td> Vertigo, confusion</td><td>4</td><td>5</td></tr><tr><td><bold>Employed</bold></td><td/><td/></tr><tr><td> yes/no</td><td>60/20</td><td>75/25</td></tr><tr><td><bold>Imaging follow-up interval</bold> (months)</td><td/><td/></tr><tr><td> 0–12</td><td>38</td><td>48</td></tr><tr><td> 12–24</td><td>18</td><td>22</td></tr><tr><td> 24–60</td><td>16</td><td>20</td></tr><tr><td> &gt;60</td><td>8</td><td>10</td></tr><tr><td/><td><bold>Median</bold></td><td><bold>Range</bold></td></tr><tr><td><bold>Lesion Size</bold> (ml)</td><td>129.0</td><td>17.3–496.2</td></tr><tr><td><bold>Radiation Dose</bold> (Gy)</td><td>60.0</td><td>40.0–60.0</td></tr></tbody></table><table-wrap-foot><fn><p><sup>#</sup>received until date of imaging, * including biopsy, resection, radiotherapy series, systemic therapy courses. ECOG: Eastern Cooperative Oncology Group, IDH: Isocitrate Dehydrogenase, NOS: Not otherwise specified, RT: Radiotherapy, TMZ: Temozolomide, CCNU: Chlorethyl-Cyclohexyl-Nitroso-Urea = Lomustin, PC: Procarbacin plus CCNU</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Patient characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><tbody><tr><td/><td>n</td><td>%</td></tr><tr><td colspan="3"/></tr><tr><td>Gender</td><td/><td/></tr><tr><td> male/female</td><td>50/30</td><td>63/37</td></tr><tr><td>Age (years)</td><td/><td/></tr><tr><td> 25–30</td><td>3</td><td>4</td></tr><tr><td> 30–40</td><td>10</td><td>13</td></tr><tr><td> 40–50</td><td>20</td><td>25</td></tr><tr><td> 50–60</td><td>26</td><td>33</td></tr><tr><td> 60–70</td><td>15</td><td>19</td></tr><tr><td> 70–80</td><td>5</td><td>6</td></tr><tr><td> 81</td><td>1</td><td>1</td></tr><tr><td>Performance Status (ECOG Scale)</td><td/><td/></tr><tr><td> ECOG 0</td><td>36</td><td>45</td></tr><tr><td> ECOG 1</td><td>37</td><td>46</td></tr><tr><td> ECOG 2</td><td>6</td><td>8</td></tr><tr><td> ECOG 3</td><td>1</td><td>1</td></tr><tr><td>Tumor Type</td><td/><td/></tr><tr><td> Glioblastoma, IDH wildtype</td><td>46</td><td>58</td></tr><tr><td> Glioblastoma, IDH mutant</td><td>8</td><td>10</td></tr><tr><td> Glioblastoma, NOS</td><td>3</td><td>4</td></tr><tr><td> Anaplastic astrocytoma, IDH wildtype</td><td>4</td><td>5</td></tr><tr><td> Anaplastic astrocytoma, IDH mutant</td><td>7</td><td>9</td></tr><tr><td> Anaplastic astrocytoma, NOS</td><td>4</td><td>5</td></tr><tr><td> Anaplastic Oligodendroglioma, IDH mutant, 1p/19q co-deleted</td><td>8</td><td>10</td></tr><tr><td>Tumor Location</td><td/><td/></tr><tr><td> frontal left/frontal right</td><td>19/19</td><td>24/24</td></tr><tr><td> parietal left/parietal right</td><td>5/5</td><td>6/6</td></tr><tr><td> temporal left/temporal right</td><td>14/12</td><td>18/15</td></tr><tr><td> occipital left/occipital right</td><td>5/1</td><td>6/1</td></tr><tr><td>Primary Treatment#</td><td/><td/></tr><tr><td> Resection + RT + TMZ/CCNU/PC</td><td>58</td><td>70</td></tr><tr><td> Biopsy + RT + TMZ/CCNU/PC</td><td>10</td><td>13</td></tr><tr><td> Resection + RT</td><td>5</td><td>6</td></tr><tr><td> Resection alone</td><td>6</td><td>8</td></tr><tr><td> Biopsy + RT</td><td>1</td><td>1</td></tr><tr><td>Total Number of Oncologic Interventions*</td><td/><td/></tr><tr><td> 1</td><td>6</td><td>8</td></tr><tr><td> 2</td><td>3</td><td>4</td></tr><tr><td> 3</td><td>61</td><td>76</td></tr><tr><td> 4</td><td>2</td><td>3</td></tr><tr><td> 5</td><td>6</td><td>8</td></tr><tr><td> 7</td><td>2</td><td>3</td></tr><tr><td>Recurrence diagnosed by FET PET</td><td/><td/></tr><tr><td> no/yes</td><td>43/37</td><td>54/46</td></tr><tr><td>Neurological Symptoms</td><td/><td/></tr><tr><td> None</td><td>25</td><td>31</td></tr><tr><td> Paresis</td><td>19</td><td>23</td></tr><tr><td> Aphasia</td><td>15</td><td>19</td></tr><tr><td> Fatigue</td><td>10</td><td>13</td></tr><tr><td> Visual Field Defect</td><td>7</td><td>9</td></tr><tr><td> Vertigo, confusion</td><td>4</td><td>5</td></tr><tr><td>Employed</td><td/><td/></tr><tr><td> yes/no</td><td>60/20</td><td>75/25</td></tr><tr><td>Imaging follow-up interval (months)</td><td/><td/></tr><tr><td> 0–12</td><td>38</td><td>48</td></tr><tr><td> 12–24</td><td>18</td><td>22</td></tr><tr><td> 24–60</td><td>16</td><td>20</td></tr><tr><td> &gt;60</td><td>8</td><td>10</td></tr><tr><td/><td>Median</td><td>Range</td></tr><tr><td>Lesion Size (ml)</td><td>129.0</td><td>17.3–496.2</td></tr><tr><td>Radiation Dose (Gy)</td><td>60.0</td><td>40.0–60.0</td></tr></tbody></table></div>#received until date of imaging, * including biopsy, resection, radiotherapy series, systemic therapy courses. ECOG: Eastern Cooperative Oncology Group, IDH: Isocitrate Dehydrogenase, NOS: Not otherwise specified, RT: Radiotherapy, TMZ: Temozolomide, CCNU: Chlorethyl-Cyclohexyl-Nitroso-Urea = Lomustin, PC: Procarbacin plus CCNU</transformed-table></extracted-table><extracted-table><table-id>t0010</table-id><table-label>Table 2</table-label><table-caption>Neurocognitive test battery.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0010"><label>Table 2</label><caption><p>Neurocognitive test battery.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Domain</th><th>Function</th><th>Test</th><th>Reference</th></tr></thead><tbody><tr><td>Attention</td><td>Processing Speed</td><td>Trail-Making Test A (TMT-A), time in seconds</td><td>(<xref rid="b0250" ref-type="bibr">Morris et al., 1989</xref>, <xref rid="b0345" ref-type="bibr">Tombaugh, 2004</xref>)</td></tr><tr><td>Executive Function</td><td>Concept Shifting</td><td>Trail-Making Test B (TMT-B), time in seconds</td><td>(<xref rid="b0250" ref-type="bibr">Morris et al., 1989</xref>, <xref rid="b0345" ref-type="bibr">Tombaugh, 2004</xref>)</td></tr><tr><td>Language</td><td>Semantic Word Fluency</td><td>DemTect:<break/>Supermarket (SM), number of correct items</td><td>(<xref rid="b0205" ref-type="bibr">Kalbe et al., 2004</xref>)</td></tr><tr><td/><td>Language Processing, Executive Functions</td><td>DemTect:<break/>Number Transcoding (NT), number of correct items</td><td>(<xref rid="b0205" ref-type="bibr">Kalbe et al., 2004</xref>)</td></tr><tr><td>Working Memory</td><td>Verbal Working Memory</td><td>DemTect:<break/>Digit Span forward // backward (DS), weighted number of correct items</td><td>(<xref rid="b0205" ref-type="bibr">Kalbe et al., 2004</xref>)</td></tr><tr><td/><td>Visual Spatial Working Memory</td><td>CorsiBlock Tapping Test forward // backward (CBT), weighted number of correct items</td><td>(<xref rid="b0030" ref-type="bibr">Berch et al., 1998</xref>)</td></tr><tr><td>Episodic Memory</td><td>Verbal Episodic Memory</td><td>DemTect: Word List, immediate (WL-IR) and delayed (WL-DR) recall, number of correct items</td><td>(<xref rid="b0205" ref-type="bibr">Kalbe et al., 2004</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>Tests were selected that allowed to assess cognitive functions in the essential domains within 25–30 min.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Neurocognitive test battery.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Domain</th><th>Function</th><th>Test</th><th>Reference</th></tr></thead><tbody><tr><td>Attention</td><td>Processing Speed</td><td>Trail-Making Test A (TMT-A), time in seconds</td><td>(???, ???)</td></tr><tr><td>Executive Function</td><td>Concept Shifting</td><td>Trail-Making Test B (TMT-B), time in seconds</td><td>(???, ???)</td></tr><tr><td>Language</td><td>Semantic Word Fluency</td><td>DemTect:Supermarket (SM), number of correct items</td><td>(???)</td></tr><tr><td/><td>Language Processing, Executive Functions</td><td>DemTect:Number Transcoding (NT), number of correct items</td><td>(???)</td></tr><tr><td>Working Memory</td><td>Verbal Working Memory</td><td>DemTect:Digit Span forward // backward (DS), weighted number of correct items</td><td>(???)</td></tr><tr><td/><td>Visual Spatial Working Memory</td><td>CorsiBlock Tapping Test forward // backward (CBT), weighted number of correct items</td><td>(???)</td></tr><tr><td>Episodic Memory</td><td>Verbal Episodic Memory</td><td>DemTect: Word List, immediate (WL-IR) and delayed (WL-DR) recall, number of correct items</td><td>(???)</td></tr></tbody></table></div>Tests were selected that allowed to assess cognitive functions in the essential domains within 25–30 min.</transformed-table></extracted-table><extracted-table><table-id>t0015</table-id><table-label>Table 3</table-label><table-caption>Neurocognitive test scores.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0015"><label>Table 3</label><caption><p>Neurocognitive test scores.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Cognitive Function</th><th>Healthy Subjects (n = 80)</th><th>Malignant Glioma Patients (n = 80)</th></tr></thead><tbody><tr><td>Attention, Processing Speed (TMT-A, seconds)</td><td>31.5 (12.2)</td><td>47.1 (33.7)***</td></tr><tr><td>Executive Function (TMT-B, seconds)</td><td>67.3 (37.9)</td><td>121.4 (83.1)***</td></tr><tr><td>Language, Word Fluency (Supermarket, items)</td><td>26.2 (5.1)</td><td>20.5 (7.8)***</td></tr><tr><td>Language Processing (Number Transcoding, items)</td><td>3.8 (0.5)</td><td>3.4 (1.0)*</td></tr><tr><td>Verbal Working Memory (Digit span forward, weighted items)</td><td>8.4 (2.1)</td><td>7.4 (2.4)**</td></tr><tr><td>Verbal Working Memory (Digit span backward, weighted items)</td><td>8.0 (2.4)</td><td>6.5 (2.5)***</td></tr><tr><td>Verbal Episodic Memory (Word list, immediate recall, items)</td><td>14.3 (2.6)</td><td>11.7 (3.8)***</td></tr><tr><td>Verbal Episodic Memory (Word list, delayed recall, items)</td><td>5.2 (2.7)</td><td>4.4 (2.8)</td></tr><tr><td>Visual Working Memory (CBT forward, weighted items)</td><td>7.5 (2.1)</td><td>6.5 (2.3)*</td></tr><tr><td>Visual Working Memory (CBT backward, weighted items)</td><td>5.6 (2.4)</td><td>4.7 (2.0)</td></tr></tbody></table><table-wrap-foot><fn><p>Average (standard deviation) neurocognitive test scores in n = 80 malignant glioma patients compared to a cohort of n = 80 healthy controls matched for age, gender, and educational status. In TMT-A/B, lower scores correspond to better performance, while in all other tests, higher scores indicate better performance. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, Mann-Whitney-U-Test</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Neurocognitive test scores.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Cognitive Function</th><th>Healthy Subjects (n = 80)</th><th>Malignant Glioma Patients (n = 80)</th></tr></thead><tbody><tr><td>Attention, Processing Speed (TMT-A, seconds)</td><td>31.5 (12.2)</td><td>47.1 (33.7)***</td></tr><tr><td>Executive Function (TMT-B, seconds)</td><td>67.3 (37.9)</td><td>121.4 (83.1)***</td></tr><tr><td>Language, Word Fluency (Supermarket, items)</td><td>26.2 (5.1)</td><td>20.5 (7.8)***</td></tr><tr><td>Language Processing (Number Transcoding, items)</td><td>3.8 (0.5)</td><td>3.4 (1.0)*</td></tr><tr><td>Verbal Working Memory (Digit span forward, weighted items)</td><td>8.4 (2.1)</td><td>7.4 (2.4)**</td></tr><tr><td>Verbal Working Memory (Digit span backward, weighted items)</td><td>8.0 (2.4)</td><td>6.5 (2.5)***</td></tr><tr><td>Verbal Episodic Memory (Word list, immediate recall, items)</td><td>14.3 (2.6)</td><td>11.7 (3.8)***</td></tr><tr><td>Verbal Episodic Memory (Word list, delayed recall, items)</td><td>5.2 (2.7)</td><td>4.4 (2.8)</td></tr><tr><td>Visual Working Memory (CBT forward, weighted items)</td><td>7.5 (2.1)</td><td>6.5 (2.3)*</td></tr><tr><td>Visual Working Memory (CBT backward, weighted items)</td><td>5.6 (2.4)</td><td>4.7 (2.0)</td></tr></tbody></table></div>Average (standard deviation) neurocognitive test scores in n = 80 malignant glioma patients compared to a cohort of n = 80 healthy controls matched for age, gender, and educational status. In TMT-A/B, lower scores correspond to better performance, while in all other tests, higher scores indicate better performance. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, Mann-Whitney-U-Test</transformed-table></extracted-table><extracted-table><table-id>t0020</table-id><table-label>Table 4</table-label><table-caption>Correlation analysis for DMN node connectivity and neurocognitive test scores.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0020"><label>Table 4</label><caption><p>Correlation analysis for DMN node connectivity and neurocognitive test scores.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><inline-graphic xlink:href="fx1.gif"/></td></tr></tbody></table><table-wrap-foot><fn><p>Correlation analysis of connectivity of DMN nodes and neurocognitive test scores in n = 80 malignant glioma patients after multimodal therapy (Pat) and in a matched cohort of healthy controls (HC). Spearman Rank-Correlation Coefficients, one-sided, *p &lt; 0.05, **p &lt; 0.01.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Correlation analysis for DMN node connectivity and neurocognitive test scores.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><tbody><tr><td/></tr></tbody></table></div>Correlation analysis of connectivity of DMN nodes and neurocognitive test scores in n = 80 malignant glioma patients after multimodal therapy (Pat) and in a matched cohort of healthy controls (HC). Spearman Rank-Correlation Coefficients, one-sided, *p &lt; 0.05, **p &lt; 0.01.</transformed-table></extracted-table></extracted-tables-set>